Elon Knoll, MD
Hematology & Oncology · Warren, MINPI 1275859704
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $508 of the $654 with a category attached, or 77.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $385 and has fallen 85.0% since, to $58 in 2025. That places this record below the midpoint for hematology & oncology clinicians in MI, where the typical reported total is $1,604.
Across 36 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$127
- Amgen$67
- Astellas Pharma US Inc$53
- E.r. Squibb & Sons, L.L.C.$46
- Sanofi$41
- Pfizer$36
- plus $284 from 13 others
Across 4 payments — averaging $157.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$632
What the payments were for
- Food & beverage$50878%
- Education$14522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 3 | $127 |
| Amgen | 4 | $67 |
| Astellas Pharma US Inc | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Sanofi | 3 | $41 |
| Pfizer | 2 | $36 |
| Merck | 2 | $32 |
| Exelixis Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 2 | $26 |
| Gilead | 2 | $25 |
| Novartis | 2 | $25 |
| Blueprint Medicines Corporation | 1 | $24 |
| Genmab U.S., Inc. | 1 | $24 |
| Sirtex Medical Inc | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Bristol Myers Squibb | 1 | $15 |
| GSK | 1 | $15 |
| Incyte Corporation | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$654 in reported general payments places this provider in the 30th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 36 | $535,658 |
| KisqaliRibociclib Succinate | 31 | $472,774 |
| ImbruvicaIbrutinib | 28 | $442,999 |
| CabometyxCabozantinib S-Malate | 17 | $431,359 |
| TasignaNilotinib Hcl | 26 | $353,522 |
| RevlimidLenalidomide | 27 | $344,872 |
| TibsovoIvosidenib | 11 | $319,474 |
| VerzenioAbemaciclib | 21 | $304,671 |
| Lenalidomide | 21 | $299,209 |
| PomalystPomalidomide | 11 | $257,369 |
| CalquenceAcalabrutinib Maleate | 12 | $177,287 |
| EliquisApixaban | 104 | $75,444 |
| Abiraterone Acetate | 23 | $48,853 |
| XareltoRivaroxaban | 29 | $26,486 |
| Anastrozole | 267 | $11,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna | $25 | $826,29657 claims |
| Exelixis Inc.Cabometyx | $31 | $431,35917 claims |
| Bristol Myers SquibbRevlimid | $15 | $344,87227 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $46 | $257,36911 claims |
| PfizerEliquis | $36 | $75,444104 claims |
| Johnson & JohnsonXarelto | $127 | $26,48629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 282 hematology & oncology providers in Michigan.
Other hematology & oncology in Warren
- Rana BilbeisiWarren$35K
- Tarik HadidWarren$8K
- Faisal MusaDearborn$976K
- Mohammed Al HallakDetroit$644K
- Daniel LebovicGrosse Pointe Woods$352K
- Sreenivasa ChandanaGrand Rapids$305K
- Mohammad ChistiTroy$180K
- Gordon SrkalovicLansing$167K
- Jeffrey ZonderDetroit$88K
- Madan AroraFlint$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.